Research Topics
| Nicola FazioSummaryAffiliation: European Institute of Oncology Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): A critical viewNicola Fazio
Unit of Upper Gastrointestinal and Neuroendocrine Tumors, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy Electronic address
Cancer Treat Rev 39:270-4. 2013..NEC are a category of NET that should be deeply studied to verify if the response to cisplatin/etoposide is homogeneous related to the different Ki67, different morphology and/or different primary site...
Langerhans' cell histiocytosisNicola Fazio
European Institute of Oncology, 20141 Milan, Italy
Lancet 365:598. 2005
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomasNicola Fazio
European Institute of Oncology, IEO NET Study Group, Via Ripamonti 435, Milan, Italy
Cancer Treat Rev 36:S87-94. 2010..Sunitinib data have been presented at the last ASCO in June 2010, and everolimus data will be presented at next ESMO in September 2010...
Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinomaN Fazio
Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
Anticancer Res 23:5023-30. 2003..The aim of this study was to evaluate the activity and safety of giving HIAC through a percutaneous catheter in pre-treated patients...
Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?N Fazio
Department of Medicine, European Institute of Oncology, Milan, Italy
Ann Oncol 18:13-9. 2007....
Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancerRoberto Biffi
Division of Abdomino Pelvic Surgery, European Institute of Oncology, Via Ripamonti 435, I 20141 Milan, Italy
World J Gastroenterol 16:868-74. 2010..To investigate feasibility, morbidity and surgical mortality of a docetaxel-based chemotherapy regimen randomly administered before or after gastrectomy in patients suffering from locally-advanced resectable gastric cancer...
Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastasesAntonio Chiappa
Department of General Surgery, European Institute of Oncology, Milano, Italy
Hepatogastroenterology 56:829-34. 2009....
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancerKatia Lorizzo
Department of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
Cancer Chemother Pharmacol 64:301-6. 2009..Second-line chemotherapy in patients with metastatic gastric cancer (MGC) pre-treated with cisplatin is not a standard option. We studied a combination of irinotecan, fluorouracil and folates...
No impact of central venous insertion site on oncology patients' quality of life and psychological distress. A randomized three-arm trialRoberto Biffi
Division of Abdomino Pelvic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
Support Care Cancer 19:1573-80. 2011..Though totally implantable access ports (TIAP) are extensively used, information from randomized trials about the impact of insertion site on patient's quality of life (QoL) and psychological distress is unavailable...
Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patientsBruno Andreoni
Dept of General Surgery, European Institute of Oncology, University of Milano, Italy
World J Surg Oncol 5:73. 2007..This study evaluates the surgical morbidity and long-term outcome of colorectal cancer surgery in an unselected group of patients treated over the period 1994-2003...
Hepatic intra-arterial chemotherapy in patients with advanced primary liver tumoursFrancesca Spada
Upper GI and NET Unit, Department of Medicine, European Institute of Oncology IEO, Via Ripamonti 435, 20141 Milan, Italy
Ecancermedicalscience 6:280. 2012..Primary liver tumours (PLTs) are currently a major health problem worldwide. The study's aim was to investigate the feasibility, toxicity, and activity of hepatic intra-arterial chemotherapy (HIAC) in patients with advanced PLTs...
Clinical response after sorafenib for hepatocellular carcinoma in elderly patients: a report of two casesFrancesca Spada
Department of Medicine, Upper Gastro Intestinal Tract and Neuroendocrine Tumors Unit, and European Institute of Oncology, Milan, Italy
Tumori 98:53e-56e. 2012..Both patients experienced minimal toxicity, suggesting that SO can be safely administered to elderly patients...
Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994-2003Antonio Chiappa
Department of General Surgery, European Institute of Oncology, Via G Ripamonti 435, 20141 Milan, Italy
Int J Colorectal Dis 20:221-30. 2005..This study reviewed the results of surgery for distal rectal cancer (where the tumour was within 6 cm of the anal verge) following the introduction of total mesorectal excision for rectal cancer in one institution...
Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapyDaris Ferrari
Department of Oncology, San Paolo Hospital, Milan, Italy
Anticancer Drugs 19:837-40. 2008..It is suggested that an aggressive regimen like ECF should be considered in fit patients who are not affected by concomitant liver disease...
Perfusion computed tomography in patients with hepatocellular carcinoma treated with thalidomide: initial experienceGiuseppe Petralia
Department of Radiology, European Institute of Oncology, University of Milan, Milan, Italy
J Comput Assist Tomogr 35:195-201. 2011..The objective of the study was to evaluate the role of perfusion computed tomography (CT) for monitoring and predicting therapy response in patients with hepatocellular carcinoma treated with thalidomide...
Successful treatment with GEMOX in patient with metastatic pancreatic adenosquamous carcinomaGaetano Aurilio
European Institute of Oncology, Medical Care Unit, Department of Medical Oncology, Milan, Italy
Tumori 97:239-42. 2011..The available therapies do not improve the poor prognosis and it is difficult to find long-term survivors (more than 1 year), even after demolitive surgery with complementary therapies...
High intensity focused ultrasound ablation of pancreatic neuroendocrine tumours: report of two casesGianluigi Orgera
Unit of Interventional Radiology, European Institute of Oncology, 20141, Milan, Italy
Cardiovasc Intervent Radiol 34:419-23. 2011..HIFU is likely to be a valid alternative for symptoms control in patients with pancreatic NETs. However, currently the procedure should be reserved for inoperable patients for whom symptoms cannot be controlled by medical therapy...
The influence of type of operation for distal rectal cancer: survival, outcomes, and recurrenceAntonio Chiappa
Dept of General Surgery, European Institute of Oncology, University of Milano, Italy
Hepatogastroenterology 54:400-6. 2007..This study analyzed the results of treatment of rectal cancer (tumor within 12 cm of the anal verge) with different techniques...
Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancerMaria Giulia Zampino
Medical Care Unit, Department of Medicine, European Institute of Oncology, Milan, Italy
Int J Radiat Oncol Biol Phys 75:421-7. 2009....
The Ligasure vessel sealer in liver resection: a pilot studyAntonio Chiappa
Department of General Surgery, European Institute of Oncology, Milano, Italy
Hepatogastroenterology 54:2353-7. 2007..This study evaluates alternative energy sources in sealing ductal structures for use in liver resection with minimal blood loss...
Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trialR Biffi
Division of Abdomino Pelvic Surgery, European Institute of Oncology, Via Ripamonti 435, I 20141 Milan, Italy
Ann Oncol 20:935-40. 2009..Central venous access is extensively used in oncology, though practical information from randomized trials on the most convenient insertion modality and site is unavailable...
Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?M G Zampino
Department of Medicine, Medical Care Unit, European Institute of Oncology, Milan, Italy
Cancer Chemother Pharmacol 63:139-48. 2008..Main biological objective was to assess sEGFR as surrogate marker of tyrosine kinase inhibition and as predictor of response...
Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor painT De Pas
Department of Medical Oncology, European Institute of Oncology, Milan, Italy
Support Care Cancer 13:194-5. 2005
Iatrogenic gastroduodenal ulcers during hepatic intra-arterial chemotherapyD Ravizza
Endoscopy Gastroenterology Division, European Institute of Oncology, Milan, Italy
Hepatogastroenterology 50:49-53. 2003..The aim of this study was to analyze a homogeneous cohort of patients in order to evaluate the evolution and management of this complication...
Oxaliplatin combined with 5-fluorouracil and methotrexate in advanced colorectal cancerM G Zampino
Division of Medical Oncology, European Institute of Milan, 20141 Milan, Italy
Anticancer Res 26:2425-8. 2006..A promising regimen including 5-Fluorouracil, methotrexate and oxaliplatin is reported...
CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumoursG Pelosi
Divisione di Anatomia Patologica e Medicina di Laboratorio, Istituto Europeo di Oncologia, Milano, Italy
Virchows Arch 437:270-4. 2000....
Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumoursD Ravizza
European Institute of Oncology, Division of Endoscopy, Via Ripamonti 435, Milan, Italy
Dig Liver Dis 39:537-43. 2007..Based on the favourable behaviour of this neoplasm, we performed an endoscopic and clinical follow-up in 11 patients affected by type 1 gastric neuroendocrine tumours, avoiding any specific treatment...
Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancerG Ferretti
Division of Medical Oncology, European Institute of Oncology, Milano, Italy
Clin Cancer Res 6:2393-400. 2000..8% test accuracy. The method proposed demonstrated to be specific, accurate, and at relatively low cost but limited by low sensitivity in detecting the presence of neoplastic cells in patients with resectable non-small cell lung cancer...
Activity and tolerability of courses of intra-arterial chemotherapy followed by chemoembolization in unresectable hepatocellular carcinomaM Colleoni
Division of Medical Oncology, European Institute of Oncology, Milan, Italy
Tumori 84:673-6. 1998..a.) chemotherapy and chemoembolization in unresectable hepatocellular carcinoma. We therefore evaluated a new program combining three courses of i.a. chemotherapy with chemoembolization administered every 28 days...
Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II studyLisa Bodei
Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti, 435 20141 Milan, Italy
Eur J Nucl Med Mol Imaging 38:2125-35. 2011..The aim of this prospective phase I-II study was to evaluate the toxicity and efficacy of (177)Lu-DOTATATE in multiple cycles...
Intrathecal chemotherapy in carcinomatous meningitis from breast cancerLaura Orlando
Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
Anticancer Res 22:3057-9. 2002..We therefore evaluated the efficacy of an ITC regimen for patients presenting with carcinomatous meningitis from breast cancer...
The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapyA Chiappa
Department of General Surgery Laparoscopic Surgery, University of Milano, European Institute of Oncology, Milano, Italy
Crit Rev Oncol Hematol 72:65-75. 2009....
Chemotherapy in pancreatic adenocarcinomaM Squadroni
Medical Division, European Institute of Oncology, Milan, Italy
Eur Rev Med Pharmacol Sci 14:386-94. 2010..Therefore, this setting should stimulate studies with new drugs and combinations and potential biological predictive factors...
Surgery for advanced colorectal cancer in elderly patients with special emphasis for radio-chemotherapy roleAntonio Chiappa
Department of General Surgery, European Institute of Oncology, University of Milano, Milano, Italy
Hepatogastroenterology 54:740-5. 2007..To compare the short- and long-term outcome of older and younger patients with advanced colorectal cancer who underwent elective surgery...
High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?T De Pas
Department of Medical Oncology, European Institute of Oncology, Milan, Italy
Ann Oncol 9:917-9. 1998..Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship. We evaluated the feasibility and toxicity of a high-dose IFO-plus-ADM combination...
Practical considerations in the treatment of hepatocellular carcinomaM Colleoni
Division of Medical Oncology, European Institute of Oncology, Milan, Italy
Drugs 55:367-82. 1998..HCC patients should be evaluated within clinical trials, possibly randomised and with homogeneous prognostic factors, in order that we may find the answer to all these important questions...
Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trialNicola Fazio
J Natl Cancer Inst 99:1345-6; author reply 1346-7. 2007
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer ResearchArnaud D Roth
Department of Oncosurgery, Oncosurgery Unit, Geneva University Hospital, Geneva 14, Switzerland
J Clin Oncol 25:3217-23. 2007....
Adjuvant chemotherapy (ECF regimen) for patients with gastric adenocarcinomaPiercarlo Saletti
Istituto Oncologico della Svizzera Italiana IOSI, Bellinzona, Switzerland
Hepatogastroenterology 54:969-72. 2007..ECF is an active regimen in advanced gastric adenocarcinoma (GAC). We used ECF as an adjuvant therapy in a cohort of patients with GAC who underwent curative surgery and describe their results in terms of feasibility and outcome...
Docetaxel in advanced gastric cancer--review of the main clinical trialsSerena Di Cosimo
Division of Medical Oncology A, Regina Elena Cancer Institute, Rome, Italy
Acta Oncol 42:693-700. 2003..The future results of the above phase III studies could indicate docetaxel as a key drug to improve treatment of patients with advanced gastric cancer...
Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumorsNicola Fazio
J Clin Oncol 22:573-4; author reply 574-5. 2004
Surgical treatment of advanced colorectal cancer in the elderlyAntonio Chiappa
Department of General Surgery, European Institute of Oncology, University of Milan
Chir Ital 57:589-96. 2005..0001) correlated significantly with overall survival rates in the elderly. Colorectal surgery for malignancy can be performed safely in the elderly with acceptable morbidity and mortality rates and long-term survival...
Successful treatment with low-dose oral chemotherapy in a patient with metastatic hepatocellular carcinomaGiovanni Di Meglio
Acta Oncol 46:1205-6. 2007
Temsirolimus for advanced renal-cell carcinomaNicola Fazio
N Engl J Med 357:1050; author reply 1050-1. 2007
Target-treatment and patients' selection: can we still neglect the timing of tissue collection?Tommaso De Pas
J Clin Oncol 23:6274-5; author reply 6275-6. 2005
Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinomaNicola Fazio
Acta Oncol 45:627-9. 2006
